FDA grants Check-Cap investigational device exemption for its prep-free CRC screening test

The FDA granted Check-Cap's C-Scan an investigational device exemption March 15 that will allow the test to launch a clinical study in the U.S.

The C-Scan test is a capsule-based screening technology used to detect polyps before they turn into cancer. The test uses an ultralow-dose X-ray capsule and a proprietary software system to generate a map of the inner lining of the colon as it travels through the gastrointestinal tract. The test requires no bowel preparation and is noninvasive. The test, however, is not a colonoscopy replacement and all positive C-Scan tests should be followed by a colonoscopy.

Check-Cap will soon launch a U.S.-based trial late this year to evaluate test performance in average-risk individuals.

Alex Ovadia, CEO of Check-Cap, said, "We believe that this highlights the FDA's recognition of C-Scan as an alternative method to address the significant unmet need for patient-friendly CRC screening, in particular since it enables the detection of CRC polyps before they may turn into cancer."

News of the approval boosted the company's stock price from around $1.50 to $4.04 at market open March 15.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like

Thank you so much for your interest in our content. Please register to access this complimentary archived content.

 

 

Already Registered? Click here to confirm.